These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

540 related articles for article (PubMed ID: 24300483)

  • 1. Pathological T0 following radical cystectomy with or without neoadjuvant chemotherapy: a useful surrogate.
    Lavery HJ; Stensland KD; Niegisch G; Albers P; Droller MJ
    J Urol; 2014 Apr; 191(4):898-906. PubMed ID: 24300483
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A precystectomy decision model to predict pathological upstaging and oncological outcomes in clinical stage T2 bladder cancer.
    Mitra AP; Skinner EC; Miranda G; Daneshmand S
    BJU Int; 2013 Feb; 111(2):240-8. PubMed ID: 22928881
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pathologic downstaging is a surrogate marker for efficacy and increased survival following neoadjuvant chemotherapy and radical cystectomy for muscle-invasive urothelial bladder cancer.
    Rosenblatt R; Sherif A; Rintala E; Wahlqvist R; Ullén A; Nilsson S; Malmström PU;
    Eur Urol; 2012 Jun; 61(6):1229-38. PubMed ID: 22189383
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neoadjuvant chemotherapy in patients with invasive bladder cancer.
    Vaughn DJ; Malkowicz SB
    Urol Clin North Am; 2005 May; 32(2):231-7. PubMed ID: 15862620
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase II trial of neoadjuvant erlotinib in patients with muscle-invasive bladder cancer undergoing radical cystectomy: clinical and pathological results.
    Pruthi RS; Nielsen M; Heathcote S; Wallen EM; Rathmell WK; Godley P; Whang Y; Fielding J; Schultz H; Grigson G; Smith A; Kim W
    BJU Int; 2010 Aug; 106(3):349-54. PubMed ID: 20089114
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Stage pT0 at radical cystectomy confers improved survival: an international study of 4,430 patients.
    Tilki D; Svatek RS; Novara G; Seitz M; Godoy G; Karakiewicz PI; Kassouf W; Fradet Y; Fritsche HM; Sonpavde G; Izawa JI; Ficarra V; Lerner SP; Schoenberg M; Stief CG; Dinney CP; Skinner E; Lotan Y; Sagalowsky AI; Reich O; Shariat SF
    J Urol; 2010 Sep; 184(3):888-94. PubMed ID: 20643448
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pathological response to neoadjuvant chemotherapy for muscle-invasive micropapillary bladder cancer.
    Meeks JJ; Taylor JM; Matsushita K; Herr HW; Donat SM; Bochner BH; Dalbagni G
    BJU Int; 2013 Jun; 111(8):E325-30. PubMed ID: 23384236
    [TBL] [Abstract][Full Text] [Related]  

  • 8. What is the significance of pT0 at cystectomy?
    Hotston M; Patel S; Sohail M; Persad RA
    Surg Oncol; 2006 Aug; 15(2):65-9. PubMed ID: 16971115
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oncologic outcomes and survival in pT0 tumors after radical cystectomy in patients without neoadjuvant chemotherapy: results from a large multicentre collaborative study.
    Rouprêt M; Drouin SJ; Larré S; Neuzillet Y; Botto H; Hitier M; Rigaud J; Crew J; Xylinas E; Salomon L; Cornu JN; Iborra F; Champetier D; Rozet F; Flamand V; Bastide C; Cormier L; Durand X; Lunardi P; Rischmann P; Nouhaud FX; Ferlicot S; Patard JJ; Floch AP; Irani J; Peyronnet B; Bensalah K; Poissonnier L; Grès P; Droupy S; Casenave J; Wallerand H; Soulié M; Pfister C;
    Ann Surg Oncol; 2011 Dec; 18(13):3833-8. PubMed ID: 21647762
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Absence of Tumor on Repeat Transurethral Resection of Bladder Tumor Does Not Predict Final Pathologic T0 Stage in Bladder Cancer Treated with Radical Cystectomy.
    Kukreja JB; Porten S; Golla V; Ho PL; Noguera-Gonzalez G; Navai N; Kamat AM; Dinney CPN; Shah JB
    Eur Urol Focus; 2018 Sep; 4(5):720-724. PubMed ID: 28753837
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Final Pathological Stage after Neoadjuvant Chemotherapy and Radical Cystectomy for Bladder Cancer-Does pT0 Predict Better Survival than pTa/Tis/T1?
    Zargar H; Zargar-Shoshtari K; Lotan Y; Shah JB; van Rhijn BW; Daneshmand S; Spiess PE; Black P;
    J Urol; 2016 Apr; 195(4 Pt 1):886-93. PubMed ID: 26521718
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Predictors of Complete Pathologic Response (pT0) to Neoadjuvant Chemotherapy in Muscle-invasive Bladder Carcinoma.
    Pokuri VK; Syed JR; Yang Z; Field EP; Cyriac S; Pili R; Levine EG; Azabdaftari G; Trump DL; Guru K; George S
    Clin Genitourin Cancer; 2016 Feb; 14(1):e59-65. PubMed ID: 26508364
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Outcome of patients who refuse cystectomy after receiving neoadjuvant chemotherapy for muscle-invasive bladder cancer.
    Herr HW
    Eur Urol; 2008 Jul; 54(1):126-32. PubMed ID: 18248875
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effect of concomitant carcinoma in situ on neoadjuvant chemotherapy for urothelial cell carcinoma of the bladder: inferior pathological outcomes but no effect on survival.
    Parker WP; Ho PL; Melquist JJ; Scott K; Holzbeierlein JM; Lopez-Corona E; Kamat AM; Lee EK
    J Urol; 2015 May; 193(5):1494-9. PubMed ID: 25451834
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Correlation of pathologic complete response with survival after neoadjuvant chemotherapy in bladder cancer treated with cystectomy: a meta-analysis.
    Petrelli F; Coinu A; Cabiddu M; Ghilardi M; Vavassori I; Barni S
    Eur Urol; 2014 Feb; 65(2):350-7. PubMed ID: 23849998
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Multicenter evaluation of the prognostic value of pT0 stage after radical cystectomy due to urothelial carcinoma of the bladder.
    May M; Bastian PJ; Burger M; Bolenz C; Trojan L; Herrmann E; Wülfing C; Müller SC; Ellinger J; Buchner A; Stief CG; Tilki D; Otto W; Höfner T; Hohenfellner M; Haferkamp A; Roigas J; Zacharias M; Wieland WF; Fritsche HM
    BJU Int; 2011 Oct; 108(8 Pt 2):E278-83. PubMed ID: 21699644
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Retrospective analysis of the efficacy of two cycles of M-VAC neoadjuvant chemotherapy followed by radical cystectomy for muscle-invasive bladder cancer.
    Kitagawa Y; Izumi K; Miwa S; Kadono Y; Konaka H; Mizokami A; Namiki M
    Anticancer Res; 2013 Oct; 33(10):4497-503. PubMed ID: 24123021
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term outcomes of selective bladder preservation by combined-modality therapy for invasive bladder cancer: the MGH experience.
    Efstathiou JA; Spiegel DY; Shipley WU; Heney NM; Kaufman DS; Niemierko A; Coen JJ; Skowronski RY; Paly JJ; McGovern FJ; Zietman AL
    Eur Urol; 2012 Apr; 61(4):705-11. PubMed ID: 22101114
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pathology-based risk stratification of muscle-invasive bladder cancer patients undergoing cystectomy for persistent disease after induction chemoradiotherapy in bladder-sparing approaches.
    Koga F; Fujii Y; Masuda H; Numao N; Yokoyama M; Ishioka J; Saito K; Kawakami S; Kihara K
    BJU Int; 2012 Sep; 110(6 Pt B):E203-8. PubMed ID: 22289431
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Timing cystectomy and perioperative chemotherapy in the treatment of muscle invasive bladder cancer.
    Izawa JI; Chin JL; Winquist E
    Can J Urol; 2006 Jun; 13 Suppl 3():48-53. PubMed ID: 16818012
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.